30
Nov
2009
The folks over at Deloitte are not so subtly pounding the drum about inevitable and dramatic change coming in life science sales methodologies – and are providing a rationale as to why pharma should in fact “blow up” the current sales force model. This is an important thesis to consider particularly if your entity is [...]
23
Nov
2009
Movetis | What’s a Blog to Do?
Posted in EX US - Movetis, IPO, X - GI
If you select the IPO category on the drop-down box here at LifeScienceDealFlow.com one can observe the tracking of the 2009 life science initial public offering story play out – you may also note perhaps a slight bias too, that is solely coverage of the US public markets have been delivered to date. Now Belgium-based [...]
18
Nov
2009
Trius Therapeutics | 5 Out, 3rd in the IPO Queue
Posted in CA Private: Trius Therapeutics, IPO, X - Antibacterial, X - MRSA
San Diego, CA-based Trius Therapeutics is looking to potentially represent the eighth biopharma IPO of the year if they are able to get out in the next month or so. With five companies trading (see matrix below), Trius is queued up alongside Anthera Pharma and Aldagen in an effort to make their Wall St. debut.
Taking [...]
17
Nov
2009
OnBioVC.com – the sister site to Life Science Deal Flow – has released the 3Q09 Trend Analysis, the .pdf can be downloaded [HERE].
Over $1,663M flowed into early-stage biopharma, diagnostic and device companies in the third quarter of 2009 and over $4,806M year-to-date!
Headquartered in Boulder, Colorado, OnBioVC provides timely coverage and comprehensive analysis of global bioscience [...]
16
Nov
2009
“You can accomplish anything in life, provided you do not mind who gets the credit.”
- Harry S. Truman
Apologies for the quiescent-state at LSDF this past week. While taking in some R&R in blissful Aspen, CO I found myself at one of my favorite bookstores, Explore Booksellers, on Main St. where an idea for a substantial [...]
04
Nov
2009
Pulmatrix | Series B $30.2 M
Posted in MA Private: Pulmatrix, Series B, X - Influenza, X - Respiratory
Based in Lexington, MA Pulmatrix is a clinical-stage pharmaceutical company developing a broad new class of inhaled therapies for the treatment and prevention of infectious and progressive respiratory diseases via a fundamentally new way approach through potentially simple and safe therapies that harness the airway and lungs own natural biophysical properties and host defense mechanisms.
Rather [...]
03
Nov
2009
Aldagen | Regenerative IPO Filing
Posted in IPO, NC Private: Aldagen, X - Stem Cell, X - Therapeutic
And the 2009 IPO class grows with the announced filing of Durham, NC-based Aldagen. The post title is a poor attempt at a double entendre – the Company had previously filed their S-1 for a planned public offering approximately 12 months ago (updated filing is [HERE]), and their business model focuses on regenerative cell therapies, [...]
01
Nov
2009
The mere fact that Burrill & WR Hambrecht are touting their team-up to focus on bringing life science companies to the public markets is certainly big news. A savvy salt & pepper life science CEO (who orchestrated a >$1B M&A of his small cap clinical-stage entity) turned managing partner of a Sand Hill Rd. [...]
Life Science Deal Flow PARTNERS
-
